

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (previously presented) A selective cytotoxic reagent comprising an onc protein having measurable ribonucleolytic activity covalently linked to an antibody directed against a surface marker specific to a B cell, wherein the cytotoxic reagent is at least 100 times more cytotoxic to target cells bearing a B cell marker than a comparison reagent comprised of the same antibody joined to the human non-toxic RNase eosinophil-derived neurotoxin (EDN).
2. (original) The reagent of claim 1, wherein the onc protein has the amino acid sequence of SEQ ID NO:1.
3. (original) The reagent of claim 1, wherein the onc protein is produced by recombinant means.
4. (original) The reagent of claim 3, wherein the onc protein has the amino acid sequence of SEQ ID NO:3
5. (original) The reagent of claim 3, wherein the onc protein is encoded by the nucleic acid molecule identified as SEQ ID NO:2.
6. (original) The reagent of claim 1, wherein the antibody is a monoclonal antibody.
7. (original) The reagent of claim 6, wherein the monoclonal antibody is humanized.
8. (original) The reagent of claim 7, wherein the monoclonal antibody is a single chain antibody.

9. (original) The reagent of claim 1, wherein the antibody is specific for B cell lymphomas.

10. (original) The reagent of claim 9, wherein the antibody is selected from the group consisting of RFB4 and LL2.

11. (original) The reagent of claim 1, wherein the surface marker is CD22.

12. (original) The reagent of claim 1, wherein the surface marker is CD74.

13. (canceled)

14. (original) The reagent of claim 1, wherein the onc protein is conjugated to the antibody through recombinant fusion.

15. (withdrawn) A nucleic acid sequence encoding the reagent of claim 1.

16. (original) A pharmaceutical composition comprising a selective cytotoxic reagent comprising an onc protein having measurable ribonucleolytic activity joined to an antibody directed against a cell surface marker specific to a B cell together with a pharmaceutically acceptable carrier.

17. (original) The pharmaceutical composition of claim 16, wherein the onc protein has the amino acid sequence of SEQ ID NO:1.

18. (original) The pharmaceutical composition of claim 16, wherein the onc protein is produced by recombinant means.

19. (original) The pharmaceutical composition of claim 18, wherein the onc protein has the amino acid sequence of SEQ ID NO:3.

20. (original) The pharmaceutical composition of claim 18, wherein the onc protein is encoded by the nucleic acid molecule identified as SEQ ID NO:2.

21. (original) The pharmaceutical composition of claim 16, wherein the onc protein is conjugated to the antibody through recombinant means.

22. (original) The pharmaceutical composition of claim 16, wherein the antibody is a monoclonal antibody.

23. (original) The pharmaceutical composition of claim 22, wherein the monoclonal antibody is humanized.

24. (original) The pharmaceutical composition of claim 23, wherein the monoclonal antibody is a single chain antibody.

25. (original) The pharmaceutical composition of claim 16, wherein the antibody is directed against a surface marker present on B cell lymphomas.

26. (previously amended) The pharmaceutical composition of claim 25, wherein the antibody is selected from the group consisting of RFB4 and LL2.

27.-34. previously cancelled

Appl. No. 09/918,887
Amdt. dated July 13, 2004
Reply to Office Action of April 14, 2004

PATENT

In response to the species election requirement set forth in the April 14, 2004 Office Action, Applicants elect CD22. In conjunction with the election of CD22, Applicants further elect RFB4. The claims that read on the elected species are claims 1-11, 14 and 16-26.

The election is made with traverse, as a proper search of the art would reasonably encompass both species as set forth by the Examiner and therefore would pose no undue burden. The Examiner is also reminded of the obligation to examine additional species once the original species is searched and determined to be free of the prior art.

If the Examiner believes a telephone conference would expedite prosecution of this application, the Examiner is invited to telephone the undersigned at 415-576-0200.

Respectfully submitted,



Carol A. Fang
Reg. No. 48,631

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
Attachments
CAF:caf
60259070 v1